The May 2026 docket lists 568 cases pending in In re Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation (2020), No. 2:20-md-02973, the proceeding JPML centralized before Judge Brian R. Martinotti in the District of New Jersey. Of 1,988 lawsuits filed, confidential settlements have steadily shrunk the active docket, as the latest JPML statistics confirm.
These vision-loss claims trace back to a drug approved in 1996 that carried no retinal-risk warning until June 2020, a 24-year gap that echoes the notice disputes driving another pharmaceutical MDL.
With no bellwether verdict on the books and confidential settlements thinning the docket, the value of the remaining claims now turns on exposure reconstruction and progression evidence rather than any public benchmark. This analysis traces the MDL's factual record, warning timeline, diagnostic pitfalls, causation disputes, and the practice consequences for counsel evaluating those claims.
How Pearce's 2018 Case Series Exposed a 24-Year Label Gap
The warning case turns on three facts: what Janssen knew, when the maculopathy association entered the ophthalmology literature, and how long the label stayed silent. For more than two decades, pentosan polysulfate sodium reached patients with no express retinal warning at all.
Pentosan polysulfate sodium (PPS) received FDA marketing approval on September 26, 1996 as the only oral treatment for interstitial cystitis. Its 2008 label carried a one-line entry under warnings: "WARNINGS: None." No ophthalmologic screening was standard in IC management.
In November 2018, Pearce and colleagues published a case series in Ophthalmology describing six patients with chronic PPS exposure who developed a distinct pigmentary maculopathy. Their symptoms included difficulty with near vision and dark adaptation, even where visual acuity stayed relatively preserved. That report marked the point later treated in the MDL as the start of the notice clock.
By September 2019, Hanif and colleagues documented the condition across multiple institutions in JAMA Ophthalmology. Those publications now matter less as current epidemiologic proof than as dated milestones in the notice-and-warning chronology.
Why Cumulative PPS Dose Drives Elmiron Causation Disputes
Causation in MDL 2973 is organized around exposure history, not a single prescribing event. That makes pharmacy records, duration of use, and the timing of visual complaints central to screening, valuation, and defense case selection alike.
At the standard 300 mg daily dose, reaching 500 grams of cumulative exposure takes roughly 4.5 to 6 years. That dose-response gradient forms the evidentiary backbone of the litigation, because risk concentrates in patients with the longest and heaviest use.
Exposure also sorts cases into valuation tiers. Files with heavier cumulative dose and foveal involvement on OCT, where central vision is directly threatened, generally occupy the top tier, while parafoveal-only findings and shorter exposure histories sit lower. Counsel on both sides reconstruct dose from pharmacy fill records, then map it against the imaging to gauge where a given plaintiff lands.
For plaintiff counsel, cumulative-dose calculation is the primary screening variable. For defense counsel, the same gradient supports individualized causation challenges against plaintiffs with lower exposure or shorter duration of use.
Reconstructing that exposure is rarely clean. Pharmacy fill records may show gaps, brand-to-generic switches, or adherence that diverged from the schedule, and each discontinuity invites argument over how much PPS a plaintiff actually absorbed. Expert testimony often bridges the records and the cumulative-dose estimate, which is why dosing experts feature on both sides of the docket.
Those exposure questions explain why the docket has retained value despite the absence of a trial verdict. Cases turn less on diagnosis alone than on whether records can reconstruct duration, dosage, and the sequence of symptoms around the June 2020 label change, the kind of aggregate-resolution dynamic common to mass tort structures.
Why PPS Maculopathy Was Misdiagnosed as AMD
Clinical mimicry shaped both treatment and litigation timing. Court records tie repeated misidentification of PPS maculopathy as more common retinal disease to continued drug use, mounting cumulative dose, and the discovery-rule disputes that followed.
A 2022 review in the Asia-Pacific Journal of Ophthalmology found the condition mimics pattern dystrophy, age-related macular degeneration (AMD), Stargardt disease, and mitochondrially inherited diabetes and deafness. Standard eye exams often missed or understated it, while fundus autofluorescence findings proved more striking than the funduscopic appearance.
Patients told they had AMD kept taking Elmiron and kept adding to their cumulative dose, unaware of any drug cause. Distinguishing PPS-induced changes from concurrent AMD requires multimodal imaging: fundus autofluorescence, OCT, and color fundus photography at minimum.
That delay reaches directly into the statute-of-limitations analysis. For plaintiffs misdiagnosed before the 2018 literature emerged, the discovery rule can govern when the limitations clock began, since a claim a patient could not reasonably have connected to a drug may not accrue until the link became knowable. In the MDL's New Jersey forum, that question runs through state limitations doctrine, which counsel must analyze plaintiff by plaintiff.
Defense counsel contest that framing case by case. They argue that a reasonably diligent patient with progressive vision changes had reason to investigate sooner, which narrows the discovery rule's reach. The dispute turns on what each plaintiff was told, when imaging first flagged an atypical maculopathy, and whether an AMD diagnosis foreclosed further inquiry.
What the June 2020 Label Change Means for Failure-to-Warn Claims
The warning timeline is the core liability narrative. The sequence is clean: a 2018 publication, a manufacturer supplement, FDA approval in 2020, and a long interval in between when the label still said nothing about retinal injury.
Janssen submitted a Prior Approval Supplement to the FDA on June 24, 2019, roughly seven to eight months after Pearce. The FDA approved the updated label on June 16, 2020, about 18 to 19 months after the November 2018 publication.
During that window, the Elmiron label stayed silent on maculopathy risk. Plaintiffs argue the FDA's Changes Being Effected (CBE) pathway let Janssen add a warning unilaterally, without prior FDA approval. Its election of the slower Prior Approval Supplement route, they contend, bears on both strict-liability adequacy and negligence.
Under Wyeth v. Levine, 555 U.S. 555 (2009), FDA approval does not preempt state failure-to-warn claims, because brand-name manufacturers can strengthen warnings through the CBE process.
The pathway choice carries practical stakes. A CBE supplement would have let the manufacturer add the retinal language as soon as it filed, months before any FDA sign-off, while the Prior Approval Supplement left the warning pending until June 2020. Plaintiffs cast that interval as avoidable; the defense frames it as appropriate deference to FDA review.
The updated label added retinal pigmentary changes to "Warnings and Precautions," noting that while "etiology is unclear, cumulative dose appears to be a risk factor." It also acknowledged the changes "may be irreversible" and "may progress even after cessation."
That language leaves both sides room. Plaintiffs emphasize that the manufacturer ultimately added a retinal warning and named cumulative dose as a risk factor.
Defense counsel point to the same review history and to the FDA's own finding that the available studies were too limited to establish a causal relationship. That dynamic, a late warning weighed against contested causation, runs through other brand-name pharmaceutical dockets, including the talcum litigation.
How Irreversible Progression Shapes Elmiron Settlement Value
Two features drive the MDL's practical significance: evidence that the injury is irreversible, and a docket that keeps shrinking. Together they shape screening, reserve-setting, and the leverage each side brings to confidential resolution.
Many claims are valued around continuing visual impairment after discontinuation rather than any transient injury. The MDL filings cite prospective and longitudinal imaging reports describing no clinical improvement after patients stopped the drug, and continued deterioration in some over extended follow-up.
The imaging itself anchors the damages theory. Fundus autofluorescence typically shows an expanding pattern of hyper- and hypoautofluorescent change at the posterior pole. OCT documents disruption of the retinal pigment epithelium that does not reverse once the drug stops, which plaintiffs use to argue a permanent injury while defense experts probe whether concurrent age-related change explains part of the picture.
That irreversibility feeds directly into valuation and settlement posture. The first bellwether trial, Maria Windham v. Janssen Pharmaceuticals, Inc., No. 2:20-cv-14670 (D.N.J. 2020), was set for January 30, 2023, then rescheduled to March 27, 2023. No trial verdicts have been rendered.
The federal MDL is not the only forum. The New Jersey Supreme Court designated the state-court Elmiron cases as multicounty litigation in December 2021, centralizing them in Bergen County for coordinated case management.
The parallel federal and state tracks mean exposure reconstruction and progression proof carry across both, and counsel weigh forum and coordination alongside the merits. Discovery and expert work frequently overlap between the two, so a ruling in one forum can shift valuation in the other.
For remaining cases, that procedural history matters in three ways:
- settlement values are shaped without a bellwether verdict establishing a public benchmark;
- medical proof and exposure reconstruction carry more weight, substituting for verdict-based valuation anchors; and
- the declining docket points to continued private resolution rather than a return to trial-centered case management.
For Plaintiff Counsel
Screening should prioritize cumulative PPS dose, treatment duration, vision complaints documented before the June 2020 label update, ophthalmologic evaluation with multimodal imaging, and temporal correlation between symptom onset and exposure thresholds. Cases with heavier cumulative exposure and foveal involvement on OCT generally occupy the highest valuation tier. Statute-of-limitations analysis must account for the discovery rule, particularly for patients misdiagnosed with AMD before 2018.
For Defense Counsel
The learned-intermediary doctrine may strengthen for prescriptions issued after June 2020, once the updated label reached prescribing physicians. Physicians who failed to take a detailed ophthalmologic history before treatment, or to order baseline and periodic retinal exams afterward, may face comparative-fault arguments.
Janssen's impossibility-preemption position looks comparatively weak given CBE availability, though the FDA review's conclusion that the data could not establish a causal relationship gives defense experts a platform for Daubert challenges. Individualized causation defenses are strongest against plaintiffs with cumulative doses below 500 grams.
Practice Implications as MDL 2973 Winds Down
MDL 2973 reads as a late-stage inventory phase, not a bellwether-driven trial phase. For plaintiff counsel, updated retinal imaging and exposure reconstruction remain the core valuation tools. For defense counsel, the strongest files are those with lower cumulative exposure, post-2020 prescribing, or competing retinal pathology.
The drop from 634 cases in March 2026 to 568 in May 2026 signals continued private resolution, even as the warning-timeline dispute and causation battles keep defining the remaining docket. For practitioners tracking how comparable failure-to-warn dockets resolve, see this related MDL analysis.
Frequently Asked Questions
How does the June 2020 label change affect post-warning prescriptions?
June 2020 functions as a dividing line for learned-intermediary arguments, because prescribing physicians then had an updated label referencing retinal pigmentary changes and cumulative dose. That does not resolve causation or warning-adequacy issues by itself, but it can materially change how warning-based claims are evaluated in later-use cases.
Why do pharmacy records matter so much in Elmiron screening?
Pharmacy records help reconstruct cumulative PPS exposure, treatment duration, and the chronology of use before and after the label change. In litigation centered on dose pattern and timing, those records often matter as much as the diagnosis itself, because they anchor both valuation and individualized causation analysis.
What evidence tends to separate stronger remaining cases from weaker ones?
Stronger files combine heavier cumulative exposure, vision complaints documented before June 2020, multimodal retinal imaging, and a temporal fit between symptom onset and long-term PPS use. Weaker files tend to involve lower exposure histories, post-2020 prescribing, or competing retinal pathology that complicates specific causation.
